Skip to main content
Erschienen in: Medical Oncology 4/2012

01.12.2012 | Original Paper

Identification and chromosomal localizations of signal transduction genes associated with human ovarian cancer metastasis

verfasst von: Zhu Xin, Xu Shenhua, Mou Hanzhou, Gu Linhui, Zhu Chihong, Liu Xianglin

Erschienen in: Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Gene chip technology can be used to identify and localize signal transduction genes associated with metastasis. We used the human genome U133A gene chip to detect differences in gene expression profiles among high (H) and low (L) metastatic human ovarian cancer cell lines (HO-8910PM, HO-8910), and normal ovarian tissues (C), to identify metastasis-associated signal transduction genes and determine their chromosomal localizations. A total of 37 signal transduction genes showed more than twofold differences in expression levels between the H and L metastatic ovarian cancer cell lines; of these, 21 genes were up-regulated [signal log ratio (SLR)  ≥ 1], and 16 genes were down-regulated (SLR  ≤ −1). Most genes were located on chromosome 1 (7 genes, 18.9%), followed by chromosome 8 (5 genes, 13.5%), then chromosomes 6, 11, and 17 (3 genes each, 8.1%). A total of 21 of the differentially expressed genes (56.7%) were localized on the short arm of the chromosome (q). The disruption of signal transduction gene expression may be an important factor associated with ovarian cancer metastasis. The affected signal transduction genes were localized to chromosomes 1, 8, 6, 11, and 17.
Literatur
1.
Zurück zum Zitat Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef
2.
Zurück zum Zitat Xu SH, Qiang LJ, Mou HZ, Ni XH, Zu CH, Zang G, Dai WF, Gao YL. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res. 1999;18:233–9. Xu SH, Qiang LJ, Mou HZ, Ni XH, Zu CH, Zang G, Dai WF, Gao YL. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res. 1999;18:233–9.
3.
Zurück zum Zitat Mou HZ, Xu SH, Zang YY, Qiang LJ, Huan XS, Zu CH, Gao YL. Establishment human ovarian cancer cell line (HO-8910) and its characterization. Chin J Obstet Gynecol. 1994;299:162–4. (in Chinese with English abstract). Mou HZ, Xu SH, Zang YY, Qiang LJ, Huan XS, Zu CH, Gao YL. Establishment human ovarian cancer cell line (HO-8910) and its characterization. Chin J Obstet Gynecol. 1994;299:162–4. (in Chinese with English abstract).
4.
Zurück zum Zitat Jalink K. Moolenaar WH.G protein-coupled receptors: the inside story. Bioessays. 2010;32(1):13–6.PubMedCrossRef Jalink K. Moolenaar WH.G protein-coupled receptors: the inside story. Bioessays. 2010;32(1):13–6.PubMedCrossRef
5.
Zurück zum Zitat Achyut BR, Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology. 2011;141(4):1167–78.PubMedCrossRef Achyut BR, Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology. 2011;141(4):1167–78.PubMedCrossRef
6.
Zurück zum Zitat Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res. 2011;71(17):5606–10.PubMedCrossRef Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res. 2011;71(17):5606–10.PubMedCrossRef
7.
Zurück zum Zitat Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA. 2003;100:8430–5.PubMedCrossRef Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA. 2003;100:8430–5.PubMedCrossRef
8.
Zurück zum Zitat Kulbe H, Levinson NR, Balkwill F, et al. The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol. 2004;48:489–96.PubMedCrossRef Kulbe H, Levinson NR, Balkwill F, et al. The chemokine network in cancer–much more than directing cell movement. Int J Dev Biol. 2004;48:489–96.PubMedCrossRef
9.
Zurück zum Zitat Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, Schettini G. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res. 2005;308:241–53.PubMedCrossRef Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, Schettini G. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res. 2005;308:241–53.PubMedCrossRef
10.
Zurück zum Zitat Tan Y, Cai SZ, Ma WF, Cai SH, Du J. The Structure and Function of SDF-1 and its receptor CXCR4 Chinese. J Biochem Mol Biol. 2004;20:1–5. Tan Y, Cai SZ, Ma WF, Cai SH, Du J. The Structure and Function of SDF-1 and its receptor CXCR4 Chinese. J Biochem Mol Biol. 2004;20:1–5.
11.
Zurück zum Zitat Xu SH, Mou HZ, Gu LH, Zu CH, Liu XL. Identification of differentially expressed genes in the high and low metastatic human ovarian cancer cell lines and analyses of their chromosomal localizations and functions. Acta Genetica Sinica. 2006;33(10):892–900.PubMedCrossRef Xu SH, Mou HZ, Gu LH, Zu CH, Liu XL. Identification of differentially expressed genes in the high and low metastatic human ovarian cancer cell lines and analyses of their chromosomal localizations and functions. Acta Genetica Sinica. 2006;33(10):892–900.PubMedCrossRef
12.
Zurück zum Zitat Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006;125:1137–49.PubMedCrossRef Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006;125:1137–49.PubMedCrossRef
13.
Zurück zum Zitat Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131(1):80–90.PubMedCrossRef Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131(1):80–90.PubMedCrossRef
14.
Zurück zum Zitat Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2011;10:CD007927.PubMed Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2011;10:CD007927.PubMed
15.
Zurück zum Zitat Zaba O, Grohe C, Merk J. Novel therapies in non-small cell lung cancer. Minerva Chir. 2011;66(3):235–44.PubMed Zaba O, Grohe C, Merk J. Novel therapies in non-small cell lung cancer. Minerva Chir. 2011;66(3):235–44.PubMed
16.
Zurück zum Zitat Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, Kalofonos HP. Targeted therapy in colorectal cancer: current status and future challenges. Curr Med Chem. 2011;18(11):1599–612.PubMedCrossRef Koutras AK, Starakis I, Kyriakopoulou U, Katsaounis P, Nikolakopoulos A, Kalofonos HP. Targeted therapy in colorectal cancer: current status and future challenges. Curr Med Chem. 2011;18(11):1599–612.PubMedCrossRef
17.
Zurück zum Zitat Suzuki Y, Saito Y, Okamura T, Tokuda Y. Gan To Kagaku Ryoho. Tykerb for breast cancer. Gan To Kagaku Ryoho. 2011;38(6):892–5.PubMed Suzuki Y, Saito Y, Okamura T, Tokuda Y. Gan To Kagaku Ryoho. Tykerb for breast cancer. Gan To Kagaku Ryoho. 2011;38(6):892–5.PubMed
Metadaten
Titel
Identification and chromosomal localizations of signal transduction genes associated with human ovarian cancer metastasis
verfasst von
Zhu Xin
Xu Shenhua
Mou Hanzhou
Gu Linhui
Zhu Chihong
Liu Xianglin
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0164-5

Weitere Artikel der Ausgabe 4/2012

Medical Oncology 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.